DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,026 filers reported holding DANAHER CORPORATION in Q2 2023. The put-call ratio across all filers is 0.79 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $14,567,040 | +279.8% | 60,696 | +298.9% | 2.52% | +202.8% |
Q1 2023 | $3,835,041 | -62.4% | 15,216 | -60.4% | 0.83% | -69.3% |
Q4 2022 | $10,190,270 | -25.6% | 38,393 | -27.6% | 2.71% | -30.3% |
Q3 2022 | $13,691,000 | +40.4% | 53,006 | +37.8% | 3.89% | +8.4% |
Q2 2022 | $9,752,000 | -10.1% | 38,466 | +4.0% | 3.59% | +13.1% |
Q1 2022 | $10,845,000 | -44.0% | 36,972 | -37.2% | 3.17% | -25.7% |
Q4 2021 | $19,361,000 | +40.3% | 58,847 | +29.8% | 4.27% | +22.4% |
Q3 2021 | $13,798,000 | -7.9% | 45,324 | -18.8% | 3.49% | +6.6% |
Q2 2021 | $14,981,000 | +2.4% | 55,824 | -14.1% | 3.28% | -3.5% |
Q1 2021 | $14,627,000 | +38.1% | 64,985 | +36.3% | 3.40% | +25.1% |
Q4 2020 | $10,593,000 | -24.3% | 47,687 | -26.6% | 2.71% | -26.8% |
Q3 2020 | $13,998,000 | +58.3% | 65,008 | +30.0% | 3.71% | +48.8% |
Q2 2020 | $8,842,000 | – | 50,000 | – | 2.49% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |